European Pharmacopoeia Ph Eur Monograph Tablets 0478 Better !!top!! -

European Pharmacopoeia (Ph. Eur.) Monograph 0478 for Tablets establishes the foundational quality and production standards for oral solid dosage forms across Europe. This monograph applies to a wide range of categories, including uncoated, film-coated, gastro-resistant, and orodispersible tablets. Key Requirements of Monograph 0478 Production Standards

: Manufacturers must ensure tablets possess suitable mechanical strength to prevent crumbling or breaking during handling. This is typically verified through Friability (2.9.7) Resistance to Crushing (2.9.8) Subdivision of Scored Tablets

: If a tablet has a break-mark to deliver fractional doses, its efficacy must be assessed. The standard requires that for 30 randomly selected tablets, no more than one individual mass of the subdivided parts can fall outside 85% to 115% of the average mass. Uniformity of Dosage Units : Tablets must comply with the test for Uniformity of Dosage Units (2.9.40)

. For tablets with less than 2 mg or 2% of active substance, Uniformity of Content (2.9.6) is usually required. Disintegration vs. Dissolution Disintegration

: Standard uncoated tablets must typically disintegrate within 15 minutes european pharmacopoeia ph eur monograph tablets 0478 better

in water. Orodispersible and soluble tablets generally have a limit of Dissolution : A suitable dissolution test (e.g.,

) is mandatory unless otherwise justified. Recent policy updates confirm that specific dissolution or disintegration tests must be included in each medicinal product monograph for immediate-release forms. Critical Technical Specifications Tablet Category Typical Disintegration Limit Testing Media 15 minutes Water (15–25 °C) Film-coated 30 minutes Water (15–25 °C) Soluble / Dispersible Water (15–25 °C) Effervescent 200 mL Water (15–25 °C) Gastro-resistant 2 hours (acid resistance) 0.1 M HCl, then pH 6.8 Buffer Recent Evolution and Updates Subdivision Accuracy

: There has been increased scrutiny on tablet divisibility, with studies showing many marketed tablets struggle to meet the strict Ph. Eur. mass uniformity requirements for subdivided parts. Harmonisation : Ongoing efforts by the Pharmacopoeial Discussion Group (PDG)

aim to further align disintegration and dissolution tests across the Ph. Eur., USP, and JP. Policy Shift (2020) European Pharmacopoeia (Ph

: The Ph. Eur. Commission decided that dissolution or disintegration tests must be included in all specific monographs for immediate-release solid dosage forms to ensure better batch-to-batch consistency.

For the most current version, including detailed testing protocols and limits, professionals should consult the latest European Pharmacopoeia 11th Edition Supplements calculation or the specific dissolution apparatus requirements? Specific monographs: Finished products

It looks like you’re trying to optimize a search or find the better version of Ph. Eur. monograph 0478 (Tablets).

Here’s a breakdown to help:

• Ph. Eur. monograph 0478 is the general monograph for Tablets. It’s been revised several times.
• The “better” version usually means the latest official corrected version (e.g., 10th Edition or current 11th Edition, with any non-included corrections from supplements).
• The current effective version (as of 2026) is found in the Ph. Eur. 11th Edition + Supplements 11.1 to 11.5 (or later, depending on when you check). The version history is tracked in the Knowledge Base of the EDQM.

To get the “better” version:

1. Go to EDQM’s official Ph. Eur. reference standards / monograph portal (subscription required).
2. Search “Tablets 0478” → view current version and compare with any earlier drafts.
3. The “better” might refer to the version where disintegration test, uniformity of mass, or dissolution requirements were clarified (e.g., changes around 7th/8th Edition).

If you don’t have access, the next best is a national pharmacopoeia that reproduces the current Ph. Eur. monograph (e.g., German or French pharmacopoeia print version).

C. Uniformity of Mass

• Reference: General Chapter 2.9.5.
• Requirement: Applies to tablets where Mass Variation is not suitable or as a general control for weight consistency. The average mass of 20 tablets typically must fall within specific percentage limits (e.g., $\pm 5%$ for tablets $> 250$ mg).

Technical Rationale Behind the Tests

• Uniformity and assay ensure each patient receives an effective and safe dose.
• Dissolution is a surrogate for in vivo release and bioavailability for many immediate-release solid oral dosage forms.
• Disintegration provides a rapid check of tablet breakup that can correlate with dissolution for certain formulations.
• Hardness/friability ensure mechanical robustness during manufacturing, packaging, and transport.
• Impurity controls protect against harmful degradation products and chemical contaminants.

2. Manufacturing & Composition Standards

The monograph mandates that tablets must be robust enough to withstand handling, packaging, and transportation while releasing the active substance correctly upon administration.

• Excipients: All excipients used must be justified and compatible with the active substance.
• Uniformity: Tablets must display uniform weight, appearance, and content.
• Physical Characteristics: They must be free from defects like cracks, capping, or lamination. They should be smooth, uniform in color, and free from foreign particulate matter.

Scope and General Requirements

The monograph applies to uncoated, film-coated, and sugar-coated tablets intended for oral administration. It does not cover specialised tablets such as effervescent, sublingual, or chewable tablets, which have separate monographs. However, for conventional immediate-release tablets, monograph 0478 is definitive. It begins with a crucial definition: “Tablets are solid preparations each containing a single dose of one or more active substances.” This clarity is essential—it distinguishes tablets from other solid forms like capsules or powders. The monograph also includes general manufacturing requirements, such as the use of suitable excipients (fillers, binders, disintegrants, lubricants) and the need for proper storage conditions. By setting these baseline expectations, monograph 0478 ensures that the physical integrity of the tablet is preserved from production line to patient. To get the “better” version :

3. Critical Quality Attributes (Testing Requirements)

The monograph outlines specific tests to ensure batch-to-batch consistency and patient safety.